Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
6.55
-0.08 (-1.21%)
At close: Feb 27, 2026, 4:00 PM EST
6.54
-0.01 (-0.15%)
After-hours: Feb 27, 2026, 7:02 PM EST
Ardelyx Revenue
In the year 2025, Ardelyx had annual revenue of $407.32M with 22.09% growth. Ardelyx had revenue of $125.22M in the quarter ending December 31, 2025, with 7.82% growth.
Revenue (ttm)
$407.32M
Revenue Growth
+22.09%
P/S Ratio
3.94
Revenue / Employee
$832,965
Employees
489
Market Cap
1.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 407.32M | 73.71M | 22.09% |
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 868.45M |
| Immunocore Holdings | 400.02M |
| Iovance Biotherapeutics | 263.50M |
| AnaptysBio | 169.47M |
| Nurix Therapeutics | 83.98M |
| Intellia Therapeutics | 67.67M |
| Relay Therapeutics | 8.36M |
ARDX News
- 4 days ago - Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions - GlobeNewsWire
- 7 days ago - Why Ardelyx's Offensive Strategy Doesn't Move The Needle - Seeking Alpha
- 8 days ago - Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability - Seeking Alpha
- 8 days ago - Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops - Benzinga
- 8 days ago - Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 - GlobeNewsWire
- 25 days ago - Ardelyx Receives New Patent for Tenapanor - GlobeNewsWire